CERA: Third-generation erythropoiesis-stimulating agent

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 5, 2008, Pages 839-849

  Topf, Joel Michels ^a  

^a ST JOHN HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

Anemia; Chronic kidney disease; Dialysis; Erythropoietin; Erythropoietin stimulating agent; Polyethylene glycol; Renal failure

Indexed keywords

ANTIANEMIC AGENT; ANTIHYPERTENSIVE AGENT; CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; FG 2216; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG; ERYTHROPOIETIN; MACROGOL DERIVATIVE;

ANEMIA; ARTERIOVENOUS FISTULA; BACKACHE; BLOOD TRANSFUSION; CHRONIC KIDNEY DISEASE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CONSTIPATION; COUGHING; DIALYSIS; DIARRHEA; DOSE RESPONSE; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHROPOIESIS; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL HEMORRHAGE; HEALTH CARE NEED; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; HYPERVOLEMIA; HYPOTENSION; KIDNEY TRANSPLANTATION; LICENSING; LIMB PAIN; LOW DRUG DOSE; MUSCLE SPASM; NONHUMAN; PATENT; PEER REVIEW; PUBLICATION; PURE RED CELL ANEMIA; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; REVIEW; RHINOPHARYNGITIS; SINGLE DRUG DOSE; THROMBOSIS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING; CHRONIC KIDNEY FAILURE; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DRUG ADMINISTRATION; EUROPEAN UNION; HALF LIFE TIME; LEGAL ASPECT; UNITED STATES;

ANEMIA; CONTROLLED CLINICAL TRIALS AS TOPIC; DRUG ADMINISTRATION SCHEDULE; ERYTHROPOIETIN; EUROPEAN UNION; HALF-LIFE; HEMATINICS; HUMANS; KIDNEY FAILURE, CHRONIC; POLYETHYLENE GLYCOLS; QUALITY OF LIFE; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 41949126749     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.9.5.839     Document Type: Review

References (57)

1. US Renal Data System. USRDS 2007 Annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2007
2. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA 2007;298:2038-47
3. Hallan SI, Coresh J, Astor BC, et al. International comparison of the relationship of chronic kidney disease prevalence and ESRD risk. J Am Soc Nephrol 2006;17:2275-84
4. Chen J, Wildman RP, Gu D, et al. Prevalence of decreased kidney function in Chinese adults aged 35 to 74 years. Kidney Int 2005;68:2837-45
5. Hsu CC, Hwang SJ, Wen CP, et al. High prevalence and low awareness of CKD in Taiwan: a study on the relationship between serum creatinine and awareness from a nationally representative survey. Am J Kidney Dis 2006;48:727-38
6. Astor BC, Muntner P, Levin A, et al. Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med 2002;162:1401-8
7. Ma JZ, Ebben J, Xia H, Collins AJ. Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol 1999;10:610-9
8. Moreno F, Sanz-Guajardo D, Lopez-Gomez JM, et al. Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients. Spanish Cooperative Renal Patients Quality of Life Study Group of the Spanish Society of Nephrology. J Am Soc Nephrol 2000;11:335-42
9. Locatelli F, Pisoni RL, Combe C, et al. Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2004;19:121-32
10. Barrett BJ, Fenton SS, Ferguson B, et al. Clinical practice guidelines for the management of anemia coexistent with chronic renal failure. Canadian Society of Nephrology. J Am Soc Nephrol 1999;10(Suppl 13):S292-6
11. National Kidney Foundation: K/DOQI clinical practice guidelines for anemia of chronic kidney disease, 2000. Am J Kidney Dis 2001;27(Suppl 1):S182-238
12. Locatelli F, Aljama P, Barany P, et al. European Best Practice Guidelines Working Group. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004;19(Suppl 2):ii1-47
13. Brunkhorst R, Bommer J, Braun J, et al. Darbepoetin alfa effectively maintains haemoglobin concentrations at extended dose intervals relative to intravenous or subcutaneous recombinant human erythropoietin in dialysis patients. Nephrol Dial Transplant 2004;19:1224-30
14. Locatelli F, Canaud B, Giacardy F, et al. Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo). Nephrol Dial Transplant 2003;18:362-9
15. Provenzano R, Bhaduri S, Singh AK. Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: the PROMPT study. Clin Nephrol 2005;64:113-23
16. Disney A, Jersey PD, Kirkland G, et al. Darbepoetin alfa administered monthly maintains haemoglobin concentrations in patients with chronic kidney disease not receiving dialysis: a multicentre, open-label, Australian study. Nephrology (Carlton) 2007;12:95-101
17. Fishbane S, Berns JS. Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. Kidney Int 2005;68:1337-43
18. Ebben JP, Gilbertson DT, Foley RN, Collins AJ. Hemoglobin level variability: associations with comorbidity, intercurrent events, and hospitalizations. Clin J Am Soc Nephrol 2006;1:1205-10
19. Regidor DL, Kopple JD, Kovesdy CP, et al. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol 2006;17:1181-91
20. Gilbertson DT, Ebben JP, Foley RN, et al. Hemoglobin level variability: associations with mortality. Clin J Am Soc Nephrol 2008;3:133-8
21. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998;339:584-90
22. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006;355:2085-98
23. Drueke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006;355:2071-84
24. Stead RB, Lambert J, Wessels D, et al. Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled, dose-escalation study in healthy volunteers. Blood 2006;108:1830-4
25. FibroGen. HIF Stabilizers: erythropoiesis. Available from: http://www.fibrogen.com/rd/hif/epo.html [Last accessed 20 February 2008]
26. Jarsch M, Brandt M, Lanzendorfer M, Haselbeck A. Comparative erythropoietin receptor binding kinetics of CERA and epoetin-beta determined by surface plasmon resonance and competition binding assay. Pharmacology 2008;81:63-9
27. Sawyer ST, Krantz SB, Goldwasser E. Binding and receptor-mediated endocytosis of erythropoietin in Friend virus-infected erythroid cells. J Biol Chem 1987;262:5554-62
28. Bailon P, Pahlke W, Brandt M, Haselbeck A. CERA (continuous erythropoiesis receptor activator) for the treatment of renal anaemia: a new agent with an innovative mechanism of action. Nephrol Dial Transplant 2003;18:166
29. Tare N, Pill J, Haselbeck A. Preclinical pharmacodynamics and pharmacokinetics of CERA (continous erythropoiesis receptor activator): a new erythropoietic agent for anaemia management in patients with kidney disease. Nephrol Dial Transplant 2003;18:166
30. MacDougall IC, Robson R, Opatrna S, et al. Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (CERA) in patients with chronic kidney disease. Clin J Am Soc Nephrol 2006;1:1211-5
31. Hirsh V, Glaspy J, Mainwaring P, et al. Phase II study of two dose schedules of CERA (Continuous Erythropoietin Receptor Activator) in anemic patients with advanced non-small cell lung cancer (NSCLC) receiving chemotherapy. Trials 2007;8:8
32. Reigner B, Jordan P, Pannier A, Dougherty FC. Phase I studies of the new erythropoietic agent, CERA (continuous erythropoiesis receptor activator): demonstration of a dose-dependent response. Nephrol Dial Transplant 2003;18:167
33. Fishbane S, Pannier A, Liogier X, et al. Pharmacokinetic and pharmacodynamic properties of methoxy polyethylene glycol-epoetin beta are unaffected by the site of subcutaneous administration. J Clin Pharmacol 2007;47:1390-7
34. de Francisco AL, Sulowicz W, Klinger M, et al. Continuous Erythropoietin Receptor Activator (CERA) administered at extended administration intervals corrects anaemia in patients with chronic kidney disease on dialysis: a randomised, multicentre, multiple-dose, phase II study. Int J Clin Pract 2006;60:1687-96
35. MIRCERA prescribing information. Available from: http://www.fda.gov/cder/ foi/label/2007/125164lbl.pdf [Last accessed 20 February 2008]
36. Locatelli F, Villa G, de Francisco AL, et al. Effect of a continuous erythropoietin receptor activator (CERA) on stable haemoglobin in patients with CKD on dialysis: once monthly administration. Curr Med Res Opin 2007;23:969-79
37. Besarab A, Salifu MO, Lunde NM, et al. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease. Clin Ther 2007;29:626-39
38. Kaufman JS, Reda DJ, Fye CL, et al. Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients. N Engl J Med 1998;339:578-83
39. Coladonato JA, Frankenfield DL, Reddan DN, et al. Trends in anemia management among US hemodialysis patients. J Am Soc Nephrol 2002;13:1288-95
40. Provenzano R, Besarab A, MacDougall IC, et al. The continuous erythropoietin receptor activator (CERA) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study. Clin Nephrol 2007;67:306-17
41. Dmoszynska A, Kloczko J, Rakicka M, et al. A dose exploration, phase I/ II study of administration of continuous erythropoietin receptor activator once every 3 weeks in anemic patients with multiple myeloma receiving chemotherapy. Haematologica 2007;92:493-501
42. Osterborg A, Steegmann JL, Hellmann A, et al. Phase II study of three dose levels of continuous erythropoietin receptor activator (CERA) in anaemic patients with aggressive non-Hodgkin's lymphoma receiving combination chemotherapy. Br J Haematol 2007;136:736-44
43. European public assessment reports: scientific discussion, Mircera H-C-739. Available from: www.emea.europa.eu/humandocs/PDFs/EPAR/mircera/ H-739-en6.pdf [Last accessed 20 February 2008]
44. Sulowicz W, Locatelli F, Ryckelynck JP, et al. Once-monthly subcutaneous CERA maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly. Clin J Am Soc Nephrol 2007;2:637-46
45. Spinowitz B, Coyne DW, Lok CE, et al. CERA maintains stable control of hemoglobin in patients with chronic kidney disease on dialysis when administered once every two weeks. Am J Nephrol 2007;28:280-9
46. Klinger M, Arias M, Vargemezis V, et al. Efficacy of intravenous methoxy polyethylene glycol-epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial. Am J Kidney Dis 2007;50:989-1000
47. Levin NW, Fishbane S, Canedo FV, et al. Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiority trial (MAXIMA). Lancet 22007;370:1415-21
48. Canaud B, Braun J, Locatelli F, et al. Intravenous (IV) CERA (continuous erythropoietin receptor activator) administered once every 2 weeks maintains stable haemoglobin (Hb) levels in patients with chronic kidney disease on dialysis. ERA-EDTA Congress; 2006 July 15-18; Glasgow, UK
49. MacDougall IC, Walker R, Provenzano R, et al. CERA (continuous erythropoietin receptor activator) administered at extended intervals corrects anemia and maintains stable Hb levels in patients with CKD not on dialysis. Am Soc Nephrol, 39th Annual Meeting; 2006 Nov 14-19; San Diego, USA
50. Vanrenterghem Y, Barany P, Mann JF, et al. Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients. Kidney Int 2002;62:2167-75
51. A study to confirm the safety and efficacy of epoetin alfa (PROCRIT®) administered perioperatively vs the standard of care in blood conservation in patients undergoing major elective spinal surgery (SPINE study, 2007). Available from: http://clinicaltrials.gov/ct/show/ NCT00211146 [Last accessed 20 February 2008]
52. Corwin HL, Gettinger A, Fabian TC, et al. Efficacy and safety of epoetin alfa in critically ill patients. N Engl J Med 2007;357:965-76
53. Eschbach JW, Abdulhadi MH, Browne JK, et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann Intern Med 1989;111:992-1000
54. Leyland-Jones BA. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 2003;4:459-60
55. Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003;362:1255-60
56. Halstenson CE, Macres M, Katz SA, et al. Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta. Clin Pharmacol Ther 1991;50:702-12
57. MacDougall IC, Gray SJ, Elston O, et al. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol 1999;10:2392-5